GSK Leads RSV Vaccine Marketing Competition

According to Reuters, the new respiratory syncytial virus (RSV) vaccine's usage has surged since its launch in the summer of 2023.

According to IQVIA data seen by Reuters, as of October 30, 2023, GlaxoSmithKline Biologicals (GSK) AREXVY™ RSV vaccine accounts for about two-thirds of RSV immunizations delivered to adults aged 60 years in the United States.

GSK's market advantage could be related to its relationship with CVS Health, the dominant pharmacy chain in the U.S.

In Canada, which approved AREXVY on August 4, 2023, RSV vaccine awareness is leveraging a hockey superstar's endorsement.

"The Arexvy ad featuring Wayne Gretzky aims to dispel the misperception that RSV is only a concern for young children and encourages adults aged 60 and older, who are among those at greater risk, to speak to their healthcare provider about RSV prevention, including the Arexvy vaccine," a GSK spokesperson told Fierce Pharma Marketing yesterday.

In Europe, the European Commission authorized AREXVY in June 2023, followed by the U.K.'s Medicines and Healthcare products Regulatory Agency in July 2023.

On July 26, 2023, GSK estimated that nearly 80 million adults in the U.S. could receive an RSV shot for the first time.

On October 31, 2023, Pfizer Inc. reported U.S. revenues from its RSV vaccine ABRYSVO™, which contributed $375 million since May 2023.

RSV vaccine uptake is influenced by the impact on adults during each RSV season. 

The World Health Organization Influenza Update N° 456, published in October 2023, reported early signs of RSV activity in parts of the European region.